医薬品製造市場：製剤別、医薬品開発タイプ別、投与経路別、薬剤別、年齢層別、流通チャネル別、治療領域別-2025～2030年世界予測

医薬品製造市場は、2023年に6,206億8,000万米ドルと評価され、2024年には6,724億4,000万米ドルに達すると予測され、CAGR 8.66%で成長し、2030年には1兆1,101億7,000万米ドルに達すると予測されています。

医薬品製造部門は、医薬品と医療療法の生産、開発、商業化を網羅し、医薬品生産における品質、効率、安全性に重点を置いています。このセクターの必要性は、世界の健康需要の高まり、慢性疾患の有病率の増加、革新的な治療への継続的なニーズによって支えられています。その用途は、API（医薬品有効成分）の生産、最終剤形の製剤化、バイオテクノロジーの進歩に及んでいます。最終用途には、病院、クリニック、研究機関、小売薬局などが含まれます。この市場に影響を与える主要成長要因には、自動化やAI統合などの技術的進歩、研究開発投資の拡大、政府の支援施策などがあります。さらに、個別化医療や生物製剤に向けた動向の高まりは、大きな成長機会をもたらしています。企業は、バイオテクノロジーの研究開発への投資、生産能力の強化、環境への影響を低減するためのサステイナブルプラクティスの採用により、こうした動向を活用することができます。

しかし、市場は厳しい規制要件、医薬品開発コストの高さ、バイオテクノロジーの統合に伴う複雑さなど、いくつかの限界や課題に直面しています。また、世界の大流行はサプライチェーンの脆弱性を浮き彫りにし、より強靭なシステムの必要性を強めています。市場関係者は、デジタルヘルスツール、先進ドラッグデリバリーシステム、製造プロセス最適化のためのビッグデータ分析の活用など、イノベーションのセグメントを探求することが奨励されます。さらに、新興諸国は医療支出の増加により市場拡大の機会をもたらしています。市場競争は激しく、革新へのプレッシャーが絶えず、市場シェアを維持するための機敏な戦略が求められます。企業は、成長を促進し、既存の障壁を克服するために、協業パートナーシップ、オープンイノベーション、戦略的買収に注力すべきです。全体として、市場情勢は科学的イノベーションと規制状況の両方によって左右されるダイナミックな性質を特徴としており、利害関係者はこの厳しい環境を乗り切り、成功を収めるために積極的かつ戦略的なアプローチを維持する必要があります。

市場力学：急速に進化する医薬品製造市場の主要市場洞察を公開

医薬品製造市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ワクチンと医薬品に対する世界の需要の増加
  • 医薬品研究開発費の増加
  • 高齢者の増加と慢性疾患の発生率
• 市場抑制要因
  • 医薬品製造に伴う高コストと複雑さ
• 市場機会
  • 医薬品製造セグメントへの投資と資金提供プログラムの増加
  • 新しい医薬品製造技術の出現
• 市場課題
  • 製薬企業に対する政府の厳しい規制

ポーターのファイブフォース：医薬品製造市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：医薬品製造市場における外部からの影響の把握

外部マクロ環境要因は、医薬品製造市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：医薬品製造市場における競合情勢の把握

医薬品製造市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：医薬品製造市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、医薬品製造市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目セグメントを網羅した包括的な市場分析を提供しています。

1.市場の浸透度：産業主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ワクチンと医薬品の世界の需要増加
    • 医薬品研究開発費の増加
    • 高齢者の増加と慢性疾患の発症率
  • 抑制要因
    • 医薬品製造に伴う高コストと複雑さ
  • 機会
    • 医薬品製造セクターにおける投資と資金調達プログラムの増加
    • 新しい医薬品製造技術の出現
  • 課題
    • 製薬会社に対する政府の厳しい規制
• 市場セグメンテーション分析
  • 製剤：注射剤の強力な研究開発を支援するための投資の急増
  • 医薬品開発タイプ：コスト効率の良さからアウトソーシング医薬品製造の利用が増加
  • 投与経路：慢性疾患の罹患率の上昇に伴い、非経口ドラッグデリバリーの研究開発活動が増加しています。
  • 医薬品：市販薬（OTC）への傾向
  • 年齢層：高齢者の病状を治療するための薬剤配合に対する大きなニーズ
  • 流通チャネル：医薬品の非小売流通チャネルの浸透
  • 治療領域：新たな腫瘍治療法の開発に向けたイノベーションの波
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境
• 顧客のカスタマイズ
  • 配合薬と市販薬の売上上位リスト 2022年

第6章 医薬品製造市場：製剤別

• イントロダクション
• カプセル
• 注射
• 粉末
• スプレー
• 懸濁液
• 錠剤

第7章 医薬品製造市場：医薬品開発タイプ別

• イントロダクション
• 社内
• アウトソーシング

第8章 医薬品製造市場：投与経路別

• イントロダクション
• 吸入
• 経口
• 非経口
• 局所

第9章 医薬品製造市場：薬剤別

• イントロダクション
• 市販薬（OTC）
• 配合薬

第10章 医薬品製造市場：年齢層別

• イントロダクション
• 成人
• 幼児と青少年
• 高齢者

第11章 医薬品製造市場：流通チャネル別

• イントロダクション
• 非小売
• 小売

第12章 医薬品製造市場：治療領域別

• イントロダクション
• アレルギー
• 心血管疾患
• 皮膚科
• 糖尿病
• 消化器内科
• 感染症
• 神経学
• 腫瘍学
• 眼科
• 疼痛管理
• 精神医療
• 肺
• 腎臓病
• 呼吸器疾患

第13章 南北アメリカの医薬品製造市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋の医薬品製造市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカの医薬品製造市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • インドの製薬産業に1,500億インドルピーの投資提案
  • Glenmark Pharma、インドで2型糖尿病治療テネリグリプチン＋ダパグリフロジン＋メトホルミンの3剤配合FDCを発売
  • NovoとTorrentが提携拡大の可能性
  • 米国FDA、Bristol Myers SquibbのReblozyl（luspatercept-aamt）を、輸血を必要とする可能性のある低リスク骨髄異形成症候群（MDS）の成人の貧血の第一選択治療として承認
  • フィンランドの製造施設が5,000万ユーロ拡大へ
  • AenovaとGalvitaが戦略的提携を締結
  • Novo Nordisk、ヒレロド製造拠点の拡大に21億ユーロを投資
  • Eli Lilly、インディアナ州での製造支出計画に16億米ドルを追加
  • FDA、ノバルティス・ミルバーン工場の米国プルビックトの商業生産を承認
  • Takeda、日本で血漿分画製剤の新製造施設に1,000億円を投資
  • Pfizerがアブゼナの生物製剤製造施設を買収

企業一覧

• AstraZeneca PLC
• Lupin Limited
• Piramal Pharma Limited
• Asymchem, Inc.
• Recipharm AB
• Biocon Limited
• AbbVie Inc.
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Pfizer, Inc.
• Merck KGaA
• Amgen Inc.
• Advent Pharma Ltd.
• Johnson & Johnson Services, Inc.
• Azurity Pharmaceuticals, Inc.
• Famar Group
• Zeon Lifesciences Ltd.
• Actiza Pharmaceutical Pvt. Ltd.
• Cipla Limited
• Aenova Group GmbH
• Boehringer Ingelheim International GmbH
• Moderna, Inc.
• Thermo Fisher Scientific Inc.
• Sun Pharmaceutical Industries Ltd.
• BioNTech SE
• Lonza Group AG
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Emcure Pharmaceuticals Limited
• Veranova, L.P.
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• Sanofi S.A.
• Novo Nordisk A/S
• Glenmark Pharmaceuticals Ltd.
• Abbott Laboratories
• GlaxoSmithKline PLC
• McKesson Corporation

LIST OF FIGURES

• FIGURE 1. PHARMACEUTICAL MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 23. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 29. PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PHARMACEUTICAL MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PHARMACEUTICAL MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 69. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 70. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 73. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 74. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 106. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 107. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 110. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 111. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 113. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 114. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 118. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 120. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 121. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 127. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 128. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 134. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 135. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 138. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 141. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 142. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 143. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 145. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 146. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 148. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 149. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 150. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 152. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 153. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 155. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 156. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 162. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 163. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 166. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 167. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 169. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 170. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 171. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 173. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 174. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 176. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 177. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 178. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 180. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 181. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 184. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 187. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 188. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 190. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 191. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 192. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 193. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 195. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 196. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 198. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 199. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 200. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 201. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 202. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 203. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 205. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 206. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 209. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 210. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 212. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 213. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 216. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 217. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 219. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 220. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 221. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 223. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 224. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 226. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 227. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 228. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 230. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 231. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 233. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 234. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 235. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 237. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 238. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 239. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 240. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 241. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 242. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 243. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 244. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 245. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 246. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 247. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 248. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 249. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 250. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 251. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 252. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 254. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 255. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 256. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 258. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 259. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 260. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 261. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 262. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 263. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 265. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 266. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 268. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 269. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 270. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 271. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 272. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 273. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 274. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 275. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 276. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 277. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 278. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 279. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 280. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 281. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 282. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 283. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 284. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 285. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 286. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 287. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 288. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 289. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 290. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 291. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 292. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 293. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 294. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 295. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 296. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 297. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 298. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 299. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 300. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 301. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 302. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 303. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 304. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 305. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 306. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 307. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 308. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 309. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
• TABLE 310. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 311. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 312. SWITZERLAND PHARMACEU

The Pharmaceutical Manufacturing Market was valued at USD 620.68 billion in 2023, expected to reach USD 672.44 billion in 2024, and is projected to grow at a CAGR of 8.66%, to USD 1,110.17 billion by 2030.

The pharmaceutical manufacturing sector encompasses the production, development, and commercialization of drugs and medical therapies, with a focus on quality, efficiency, and safety in the production of medicinal products. The necessity of this sector is underpinned by the growing global health demands, increasing prevalence of chronic diseases, and the continuous need for innovative therapeutics. Its applications span across the production of APIs (Active Pharmaceutical Ingredients), formulation of finished dosage forms, and advancements in biotechnology. The end-use scope includes hospitals, clinics, research institutes, and retail pharmacies. Key growth factors influencing this market include technological advancements such as automation and AI integration, growing R&D investments, and supportive government policies. Additionally, the rising trend towards personalized medicine and biologics offers significant growth opportunities. Companies can capitalize on these trends by investing in biotech R&D, enhancing their production capabilities, and adopting sustainable practices to reduce environmental impact.

However, the market faces several limitations and challenges, such as stringent regulatory requirements, high costs of drug development, and the complexities involved in biotechnology integration. The global pandemic has also highlighted vulnerabilities in supply chains, reinforcing the need for more resilient systems. Market players are encouraged to explore areas of innovation like digital health tools, advanced drug delivery systems, and the use of big data analytics for optimizing manufacturing processes. Additionally, developing countries present opportunities for market expansion due to increasing healthcare expenditure. The market is highly competitive, with continuous pressure to innovate, demanding agile strategies to maintain market share. Companies should focus on collaborative partnerships, open innovation, and strategic acquisitions to drive growth and overcome existing barriers. Overall, the pharmaceutical manufacturing market is characterized by its dynamic nature, driven by both scientific innovation and regulatory landscapes, thus requiring stakeholders to maintain a proactive and strategic approach to navigate and thrive in this challenging environment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Manufacturing Market

The Pharmaceutical Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in global demand for vaccines and drugs
  • Growing pharmaceutical R&D spending
  • Growth in geriatric population and incidence rate of chronic disorders
• Market Restraints
  • High costs and complexities associated with the pharma production
• Market Opportunities
  • Rise in the investment and funding programs in the pharmaceutical manufacturing sector
  • Emergence of novel pharmaceutical manufacturing technologies
• Market Challenges
  • Stringent government regulations for pharmaceutical companies

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Manufacturing Market

A detailed market share analysis in the Pharmaceutical Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Lupin Limited, Piramal Pharma Limited, Asymchem, Inc., Recipharm AB, Biocon Limited, AbbVie Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Pfizer, Inc., Merck KGaA, Amgen Inc., Advent Pharma Ltd., Johnson & Johnson Services, Inc., Azurity Pharmaceuticals, Inc., Famar Group, Zeon Lifesciences Ltd., Actiza Pharmaceutical Pvt. Ltd., Cipla Limited, Aenova Group GmbH, Boehringer Ingelheim International GmbH, Moderna, Inc., Thermo Fisher Scientific Inc., Sun Pharmaceutical Industries Ltd., BioNTech SE, Lonza Group AG, Novartis AG, F. Hoffmann-La Roche Ltd., Emcure Pharmaceuticals Limited, Veranova, L.P., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Sanofi S.A., Novo Nordisk A/S, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, GlaxoSmithKline PLC, and McKesson Corporation.

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Formulation, market is studied across Capsules, Injectable, Powders, Sprays, Suspensions, and Tablets.
• Based on Drug Development Type, market is studied across In-House and Outsource.
• Based on Route of Administration, market is studied across Inhalations, Oral, Parenteral, and Topical.
• Based on Drugs, market is studied across Over-the-Counter (OTC) Medicines and Prescription Medicines.
• Based on Age Group, market is studied across Adults, Children & Adolescents, and Geriatric.
• Based on Distribution Channel, market is studied across Non-Retail and Retail.
• Based on Therapy Area, market is studied across Allergy, Cardiovascular Diseases, Dermatology, Diabetes, Gastroenterology, Infectious Disease, Neurology, Oncology, Ophthalmology, Pain Management, Psychiatry, Pulmonary, Renal Disease, and Respiratory Diseases.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in global demand for vaccines and drugs
    • 5.1.1.2. Growing pharmaceutical R&D spending
    • 5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
  • 5.1.2. Restraints
    • 5.1.2.1. High costs and complexities associated with the pharma production
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise in the investment and funding programs in the pharmaceutical manufacturing sector
    • 5.1.3.2. Emergence of novel pharmaceutical manufacturing technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations for pharmaceutical companies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Formulation: Surging investment to support robust research and development of injectable formulations
  • 5.2.2. Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness
  • 5.2.3. Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease
  • 5.2.4. Drugs: Inclination toward Over-the-counter (OTC) drugs
  • 5.2.5. Age Group: Significant need for drug formulations to treat geriatric medical conditions
  • 5.2.6. Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals
  • 5.2.7. Therapy Area: Wave of innovations toward development of new oncology treatment modalities
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization
  • 5.5.1. List of Top Selling Prescription and Over-the-Counter Drugs in 2022

6. Pharmaceutical Manufacturing Market, by Formulation

• 6.1. Introduction
• 6.2. Capsules
• 6.3. Injectable
• 6.4. Powders
• 6.5. Sprays
• 6.6. Suspensions
• 6.7. Tablets

7. Pharmaceutical Manufacturing Market, by Drug Development Type

• 7.1. Introduction
• 7.2. In-House
• 7.3. Outsource

8. Pharmaceutical Manufacturing Market, by Route of Administration

• 8.1. Introduction
• 8.2. Inhalations
• 8.3. Oral
• 8.4. Parenteral
• 8.5. Topical

9. Pharmaceutical Manufacturing Market, by Drugs

• 9.1. Introduction
• 9.2. Over-the-Counter (OTC) Medicines
• 9.3. Prescription Medicines

10. Pharmaceutical Manufacturing Market, by Age Group

• 10.1. Introduction
• 10.2. Adults
• 10.3. Children & Adolescents
• 10.4. Geriatric

11. Pharmaceutical Manufacturing Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Non-Retail
• 11.3. Retail

12. Pharmaceutical Manufacturing Market, by Therapy Area

• 12.1. Introduction
• 12.2. Allergy
• 12.3. Cardiovascular Diseases
• 12.4. Dermatology
• 12.5. Diabetes
• 12.6. Gastroenterology
• 12.7. Infectious Disease
• 12.8. Neurology
• 12.9. Oncology
• 12.10. Ophthalmology
• 12.11. Pain Management
• 12.12. Psychiatry
• 12.13. Pulmonary
• 12.14. Renal Disease
• 12.15. Respiratory Diseases

13. Americas Pharmaceutical Manufacturing Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Pharmaceutical Manufacturing Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. INR 15,000 Crore Proposed in Pharma Sector, India
  • 16.3.2. Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes
  • 16.3.3. Novo, Torrent may Widen Tie-Up
  • 16.3.4. U.S. FDA Approves Bristol Myers Squibb's Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
  • 16.3.5. Finnish Manufacturing Facility to Get EUR 50 Million Expansion
  • 16.3.6. Aenova and Galvita Enter Strategic Partnership
  • 16.3.7. Novo Nordisk Invests EUR 2.1 Billion in Hillerod Manufacturing Expansion
  • 16.3.8. Eli Lilly Adds USD 1.6 Billion to its Manufacturing Spending Plan in Indiana
  • 16.3.9. FDA Approves Novartis Millburn Facility for U.S. Commercial Production of Pluvicto
  • 16.3.10. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
  • 16.3.11. Pfizer Acquires Abzena's Biologic Manufacturing Facility

Companies Mentioned

• 1. AstraZeneca PLC
• 2. Lupin Limited
• 3. Piramal Pharma Limited
• 4. Asymchem, Inc.
• 5. Recipharm AB
• 6. Biocon Limited
• 7. AbbVie Inc.
• 8. Bayer AG
• 9. Takeda Pharmaceutical Company Limited
• 10. Eli Lilly and Company
• 11. Pfizer, Inc.
• 12. Merck KGaA
• 13. Amgen Inc.
• 14. Advent Pharma Ltd.
• 15. Johnson & Johnson Services, Inc.
• 16. Azurity Pharmaceuticals, Inc.
• 17. Famar Group
• 18. Zeon Lifesciences Ltd.
• 19. Actiza Pharmaceutical Pvt. Ltd.
• 20. Cipla Limited
• 21. Aenova Group GmbH
• 22. Boehringer Ingelheim International GmbH
• 23. Moderna, Inc.
• 24. Thermo Fisher Scientific Inc.
• 25. Sun Pharmaceutical Industries Ltd.
• 26. BioNTech SE
• 27. Lonza Group AG
• 28. Novartis AG
• 29. F. Hoffmann-La Roche Ltd.
• 30. Emcure Pharmaceuticals Limited
• 31. Veranova, L.P.
• 32. Bristol-Myers Squibb Company
• 33. Gilead Sciences, Inc.
• 34. Sanofi S.A.
• 35. Novo Nordisk A/S
• 36. Glenmark Pharmaceuticals Ltd.
• 37. Abbott Laboratories
• 38. GlaxoSmithKline PLC
• 39. McKesson Corporation